Peer reviewed
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Phase 3 trial of tirzepatide for obesity showing mean weight loss of 22.5% at 72 weeks at the highest dose.
New England Journal of MedicinePublished 2022-07-21Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-tirzepatide-surmount1-2022
Source usage
Linked from 8 pages
Compound
Tirzepatide
ComparisonRetatrutide vs Tirzepatide
ComparisonSemaglutide vs Tirzepatide for Weight Loss
ComparisonTirzepatide vs Semaglutide
Evidence curationBest Peptides for Weight Loss
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Terminology Glossary
Research hubCompounded Peptides Explained: 503A vs 503B
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.